Pharmaceutical Technology
APRIL 22, 2024
Discover how BioMarin Pharmaceutical's patent for PAL variants offers a groundbreaking method to treat PKU in adolescents. Administering AvPAL variants weekly over 50 weeks effectively reduces blood phenylalanine levels.
Bio Pharma Dive
APRIL 22, 2024
A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of the complex cellular treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
APRIL 21, 2024
An article by Aloiz Kara Aging represents a risk factor for many health problems and diseases, which means that as we grow older, there is a high probability that our health will change negatively. While some of those health issues could be attributed to a hectic lifestyle, the same way of living could keep you from getting the necessary prescribed medicine.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 21, 2024
Not getting enough sleep is a common affliction in the modern age. If you don’t always get as many hours of shut-eye as you’d like, perhaps you were concerned by news of a recent study that found people who sleep less than six hours a night are at higher risk of type 2 diabetes.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
APRIL 22, 2024
Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.
Bio Pharma Dive
APRIL 22, 2024
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
APRIL 21, 2024
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies could limit the adverse effects seen with current drugs.
Pharmaceutical Technology
APRIL 22, 2024
Discover how Avidity Biosciences' patented polynucleic acid molecule conjugate targets the DUX4 gene to combat FSHD. Learn more about this groundbreaking approach in gene therapy.
Bio Pharma Dive
APRIL 22, 2024
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
Pharma Mirror
APRIL 21, 2024
The healthcare industry is actively digitalizing and employing modern tools to enrich the grade of service. Clinics incorporate virtual waiting rooms, among other software, to boost patient care and improve staff workflow in traditional medical establishments. In this guide, we’ll investigate the advantages of virtual hospital waiting rooms and how they are revolutionizing healthcare.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
APRIL 21, 2024
Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers.
Pharmaceutical Technology
APRIL 22, 2024
Develop a stable cell line for high-titer rAAV production with Ultragenyx's patented method involving HDAC inhibitors and AAV rep proteins. Explore the groundbreaking patent now!
Bio Pharma Dive
APRIL 22, 2024
Treatment delays can seriously impact patients’ health outcomes. But by leveraging digital tools, pharma can help them find and access specialist care early in their journey.
Pharma Mirror
APRIL 21, 2024
The healthcare landscape is rapidly transforming, fueled by the convergence of technology and medicine. Among the myriad of innovations, the Internet of Things (IoT) stands out as a beacon of hope, promising to revolutionize patient care, streamline operations, and enhance medical outcomes. As we delve into the IoT in Healthcare Market Outlook for 2031, the data paints a vivid picture of an industry poised for unprecedented growth and innovation.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
APRIL 22, 2024
According to data and analytics firm GlobalData, the burden of hospitalized incident cases of methicillin-resistant Staphylococcus aureus (MRSA) is set to grow from 714,000 to 791,000 cases by 2023.
Pharmaceutical Technology
APRIL 22, 2024
Wave Life Sciences Ltd patent reveals a groundbreaking method for synthesizing high-purity oligonucleotides with increased yields. Learn more about this innovative process now!
Bio Pharma Dive
APRIL 22, 2024
A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.
BioSpace
APRIL 21, 2024
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, Akero Therapeutics is developing what may serve as a viable alternative treatment for precirrhotic disease.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioPharma Reporter
APRIL 22, 2024
After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers.
Pharmaceutical Technology
APRIL 22, 2024
Radius Pharmaceuticals presented real-world evidence at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases on 12 April 2024, demonstrating that Tymlos therapy resulted in a lower incidence of hip and nonvertebral fractures compared to teriparatide therapy in women with osteoporosis aged 50 and older.
Bio Pharma Dive
APRIL 22, 2024
The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.
BioSpace
APRIL 21, 2024
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioPharma Reporter
APRIL 22, 2024
Ahead of CPHI North America, we caught up with Lisa Stiles, director, business development at Selkirk Pharma, an exhibitor at the event, to find out how the CMO is navigating regulatory changes, challenges and more.
Pharmaceutical Technology
APRIL 22, 2024
Discover the groundbreaking patent by Purdue Pharma for treating T-cell prolymphocytic leukemia with tinostamustine. Learn about the innovative kit and dosage guidelines for effective T-PLL treatment.
pharmaphorum
APRIL 22, 2024
Pharmaceutical companies stand to gain significant benefits from technological innovation in the form of improved data analytics, streamlined healthcare processes, and enhanced patient outcomes. Explore the potential advantages for the pharma industry.
BioSpace
APRIL 21, 2024
As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioPharma Reporter
APRIL 22, 2024
Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S. market.
Pharmaceutical Technology
APRIL 22, 2024
Discover how Teladoc Health Inc's patent revolutionizes video search with a telepresence device, efficiently retrieving relevant segments based on situational data. Improve user experience and streamline access to pertinent information with this innovative technology.
Pharma Times
APRIL 22, 2024
The neurodegenerative condition currently affects more than 944,000 people living in the UK
BioSpace
APRIL 21, 2024
The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
235 
Let's personalize your content